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Background: Staphylococcus pseudintermedius is an opportunistic pathogen recognized as the leading cause of
skin, ear, and post-operative bacterial infections in dogs and cats. Zoonotic infections have also recently been
reported causing endocarditis, infection of surgical wounds, rhinosinusitis, and catheter-related bacteremia. The aim of
the present study is to evaluate, for the first time, the pathogenic potential of S. pseudintermedius isolated from a
human infection. To this end, strain DSM 25713, which was recently isolated from a wound of a leukemic patient
who underwent a bone marrow transplantation, was investigated for biofilm formation and antibiotic-resistance
under conditions relevant for wound infection.
Results: The effect of pH (5.5, 7.1, and 8.7) and the presence of serum (diluted at 1:2, 1:10, and 1:100) on biofilm
formation was assessed through a crystal violet assay. The presence of serum significantly reduced the ability to
form biofilm, regardless of the pH value tested. In vitro activity of eight antibiotics against biofilm formation and
mature 48 h-old biofilms was comparatively assessed by crystal violet assay and viable cell count, respectively.
Antibiotics at sub-inhibitory concentrations reduced biofilm formation in a dose-dependent manner, although
cefoxitin was the most active, causing a significant reduction already at 1/8xMIC. Rifampicin showed the highest
activity against preformed biofilms (MBEC90: 2xMIC). None of the antibiotics completely eradicated the preformed
biofilms, regardless of tested concentrations. Confocal and electron microscopy analyses of mature biofilm revealed a
complex “mushroom-like” architecture consisting of microcolonies embedded in a fibrillar extracellular matrix.
Conclusions: For the first time, our results show that human wound-associated S. pseudintermedius is able to
form inherently antibiotic-resistant biofilms, suggestive of its pathogenic potential, and consistent with recent reports of
zoonotic infections.
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Staphylococcus pseudintermedius, the prevalent species
in the Staphylococcus intermedius Group, is an oppor-
tunistic pathogen recognized as the leading cause of
skin, ear, and post-operative bacterial infections in dogs
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unless otherwise stated.Human infection, mainly acquired from dogs, has how-
ever only recently been reported. The first case of human
infection by S. pseudintermedius was described in 2006 by
Van Hoovels et al. [3] causing endocarditis after the im-
plantation of a cardioverter-defribrillator device (ICD).
Since then, human infections have been reported sporad-
ically, including surgical site infections, rhinosinusitis, and
catheter associated bacteremia [4–6].
The last published case of human S. pseudintermedius
infection, the second case involving a methicillin-resistant
strain, recently arrived at our observation [7]. A 65-year-
old male patient who received an allogeneic bone marrowal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ted to the “Spirito Santo” Hospital of Pescara (Italy), be-
cause of a wound infection. The lesion, secondary to the
chronic Graft-versus-Host Disease (GvHD) that compli-
cated the transplant, was located in the periumbilical re-
gion and showed two different purulent discharges that
grew S. pseudintermedius, namely strain DSM (Deutsche
Sammlung von Mikroorganismen und Zellkulturen, GmbH)
25713. The patient had a history of close association with
a companion dog, as well as farm cows.
Knowledge of the pathogenesis of S. pseudintermedius
remains yet limited. It is known that veterinary strains
are able to produce numerous virulence factors, including
β-hemolysin, clumping factor, coagulase, DNase, protein
A, lipase, leukotoxin, exfoliative toxin, and enterotoxins
[8, 9]. Furthermore, S. pseudintermedius methicillin-
resistant strains have recently emerged as a major chal-
lenge, for veterinary dermatologists in particular, owing to
their extensive multidrug resistance and their behavior as
nosocomial pathogens [10].
Biofilm formation is considered to be one of the most
important virulence factors in staphylococci, especially
for Staphylococcus aureus and Staphylococcus epidermi-
dis, as it allows them to adhere to tissues and indwelling
medical devices [11].
A biofilm is a structured consortium of bacteria ad-
hered to a substratum and embedded in a self-produced
extracellular polymer substance (EPS) consisting of poly-
saccharide, protein and DNA. Bacterial biofilms are of
clinical relevance since they confer resistance to antibi-
otics and disinfectants, as well as resistance to phagocyt-
osis and the host immune system generally, all factors
promoting chronic infections.
Biofilm forming ability of veterinary S. pseudinterme-
dius isolates has been reported, although not extensively
[8, 12–14]. Most strains were identified as biofilm-
producers [14], although isolates belonging to the most
frequent sequence type observed in Europe, ST71, had a
significantly greater ability to produce biofilm [12], with
strains from canine conjunctivitis also demonstrating in-
creased production [8].
Although the presence of virulence factors such as
DNase, β-hemolysin, coagulase, and leukotoxins was also
observed in S. pseudintermedius strains isolated from
humans [3, 5], to the best of our knowledge the potential
for biofilm formation of these strains has yet to be
investigated.
Therefore, the present work was aimed at assessing,
for the first time in literature, the ability of a human S.
pseudintermedius strain to form biofilm, as well as its
pathogenic potential. In this regard, biofilm formation
by the wound isolate S. pseudintermedius strain DSM
25713 was evaluated under different conditions relevant
for wound site (i.e. different concentrations of serum,tested as free or substratum-adsorbed; and different pH
values suggestive of acid, neutral and basic wound envi-
ronments), and in the presence of eight antibiotics tested
at both sub-inhibitory and bactericidal concentrations
against biofilm formation and preformed (mature) bio-
films, respectively. Biofilm architecture and kinetics of
formation were further studied using both scanning elec-
tron and confocal laser scanning microscopy.
Overall, our results clearly show that S. pseudinterme-
dius strain DSM 25713 is able to form a biofilm ultrastruc-
turally complex that is inherently resistant to antibiotics,
confirming the pathogenic potential of this bacterium to
cause human disease.
Materials and methods
Bacterial strain and growth conditions
The strain S. pseudintermedius DSM 25713 was isolated
from a wound of a haematologic patient recently admitted
to “Santo Spirito” Hospital in Pescara, Italy [7]. Strain
identification was carried out using biochemical tests (API
system; bioMerieux, Marcy l’Etoile, France), and con-
firmed by 16S RNA sequencing. Bacterial stocks were
stored at −80 °C until their use, when they were thawed,
inoculated into Trypticase Soy broth (TSB; Oxoid SpA,
Garbagnate M.se, Italy), and incubated at 37 °C for 24 h.
An aliquot was then plated twice on Mueller-Hinton agar
(MHA; Oxoid SpA) to check for the purity of the culture.
A standardized suspension of 1.0 × 108 CFU/mL (corre-
sponding to OD of 1.0 at 550 nm) was prepared in TSB
and used immediately for all experiments.
Standardization and optimization of S. pseudintermedius
biofilm growth on polystyrene
Since the optimal conditions for S. pseudintermedius bio-
film formation on polystyrene surfaces are not known,
preliminary experiments were carried out to optimize and
standardize the in vitro model for biofilm formation. The
following basic parameters for biofilm growth were con-
sidered for optimization: i) inoculum size (suspensions at
105, 106, and 107 CFU/ml were prepared starting from
standardized inoculum); ii) dynamic (cultures were incu-
bated under agitation at 200 rpm) (IKA agitator KS 260;
IKA, Milan, Italy) or static conditions; and iii) incubation
time (24, 48, and 72 h).
Based on our results, an inoculum size of 107 CFU/ml,
and static incubation were used for S. pseudintermedius
biofilm formation, while susceptibility to antibiotics was
tested by exposing 48 h-biofilms to antibiotic for a fur-
ther 24 h.
Quantitative measurement of static biofilms
In brief, 200 μl of the standardized inoculum at desired
concentration prepared in TSB (Oxoid SpA) was added
aseptically to each well of a 96-well polystyrene tissue
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pany, Milan, Italy), and incubated at 37 °C under static
conditions. Wells that only contained TSB were consid-
ered as controls. At the end of the incubation, spent
medium was discarded and each well was washed twice
with PBS (pH 7.2) (Sigma-Aldrich Srl, Milan, Italy) to re-
move non-adherent cells. Biofilm formation was then
assessed by crystal violet assay or viable cell count. i)
Crystal violet microtiter plate assay [15]. Biofilm samples
were fixed by incubating plates at 60 °C for 1 h, then
stained for 5 min with 200 μl Hucker-modified crystal
violet [16]. Excess stain was rinsed off with running tap
water, and then the plates were air-dried. Crystal violet
was extracted by exposure at room temperature for
15 min to 200 μl glacial acetic acid 33 % (Sigma-Al-
drich), and biofilm biomass (including adherent bacteria
and EPS) was then assessed by measuring the optical
density at 492 nm (OD492) (SpectraMax 190; Molecular
Devices, Sunnyvale, CA, USA). ii) Total viable cell count.
In each well, the biofilm sample was scraped by using a
pipette tip after 5-min exposure to 200 μl trypsin-EDTA
0.25 % (Sigma-Aldrich), then resuspended in sterile PBS
by vortexing. Serial 10-fold dilutions of each sample
were prepared in sterile PBS and 100 μl of each dilution
was plated on MHA and incubated at 37 °C for 24 h.
Colonies were counted to estimate biofilm viability.Continuous flow through biofilm
Biofilm was allowed to form in a polycarbonate flow
through chamber (The Technical University of Denmark,
Lyngby, Denmark) for microscopic studies [17]. The flow
cell is composed of three parallel channels in perspex
(poly[methyl methacrylate]), covered with a no. 1 24 ×
50 mm glass coverslip which serves as the biofilm substra-
tum. Each channel has a dimension (length × width ×
height) of 40 × 4 × 4 mm and was cleaned with 96 % (v/v)
ethanol prior to use.
In brief, the chamber was inoculated with standardized
inoculum diluted in TSB at 5 × 105 CFU/ml, then inverted
to allow microorganisms to attach for 3 h, under static
conditions, at 37 °C. The flow cell was then placed upright
and the pump started with a TSB flow rate of 0.5 ml/min.
Biofilm was allowed to form for 24 h at 37 °C, then
washed with PBS (2 min at 0.5 ml/min), and finally ob-
served by a confocal laser scanning microscope.Time course of biofilm formation
Biofilms were allowed to form in each well of a 24-well
flat-bottom polystyrene tissue-treated microtiter plate
(BD Company), as described above. At selected times
(30 min, 1, 2, 4, 8, 24, 48, and 72 h of incubation) bio-
film viability was assessed by viable colony count as de-
scribed above. In a parallel series of experiments, wellswere broken and fragments representative of each time
point were observed by scanning electron microscopy.
Effect of human serum and pH on biofilm formation
Serum for testing was pooled from multiple samples.
Serum samples were collected from 30 blood donors,
which were selected based on their health status as non-
smokers with no other known current diseases, and be-
cause they were not on any medications. The serum
samples were then pooled, aliquoted, and stored at −20 °C
until use. Since it was observed that albumin and total
protein levels were significantly higher in serum than in
wound fluid [18], serum was tested against biofilm forma-
tion at different dilutions (1:2, 1:10, and 1:100) prepared in
TSB. Serum was tested both as free (soluble) and adhered
to polystyrene. In the latter case, serum-coated micro-
plates were prepared immediately before use. In brief,
200 μl of serum was added to each well of a 96-well tissue
culture plates (BD Company), incubated for 2 h at 37 °C,
then washed by PBS to remove excess serum.
The effect of pH and serum on S. pseudintermedius bio-
film formation was simultaneously assessed. To this end,
96-well microtiter plates containing free or adsorbed serum
were inoculated with the standardized inoculum prepared
in TSB that was previously corrected at different pH
values (5.5, 7.1, and 8.7) by using HCl or NaOH 1 M solu-
tion, then incubated at 37 °C for 24 h. Biofilm biomass
levels were then spectrophotometrically measured as de-
scribed above.
Susceptibility assays
Susceptibility of S. pseudintermedius strain DSM 25713 to
chloramphenicol, gentamicin, cefoxitin, linezolid, rifampi-
cin, vancomycin, tetracycline, and tigecycline (all were
purchased, as reference powders, from Sigma-Aldrich)
was determined by microdilution technique, in accordance
with CLSI M100-S20 guidelines [19]. MIC was calculated
as the lowest concentration of the test agent that com-
pletely inhibited visible growth. MBC was evaluated as the
lowest concentration of the test agent killing of at least
99.99 % of the original inoculum. E. faecalis ATCC29212
and E. coli ATCC25922 were used as reference strains.
Antibiotic activity against biofilm formation
In each well of a 96-well flat-bottom polystyrene tissue-
culture microtiter plate (Becton, Dickinson and Com-
pany), 5 μl of a standardized inoculum (1–5 × 107 CFU/
ml) were added to 100 μl of cation-adjusted Mueller-
Hinton broth (CAMHB; Oxoid SpA) containing antibiotic
at 1/2×, 1/4×, and 1/8×MIC. After incubation at 37 °C for
24 h, non-adherent bacteria were removed by washing
twice with 100 μl sterile PBS, then biofilm levels were
spectrophotometrically measured as described above.
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The activity of antibiotics against 48 h-old biofilms was
assessed by viable colony count. Biofilms were allowed
to form in each well of a 96-well flat-bottom polystyrene
tissue-treated microtiter plate (Becton, Dickinson and
Company), as described above. Following 48 h-incuba-
tion, biofilms samples were washed twice with PBS, then
exposed to 200 μl of drug-containing CAMHB (prepared
at 1, 2, 4, 8, 16, 32, 64, and 128 × MIC). After incuba-
tion at 37 °C for 24 h, non-adherent bacteria were re-
moved by washing twice with 200 μl sterile PBS, and
biofilm samples were scraped as described above. Cell
suspension was then vortexed for 1 min to break up bac-
terial clumps. Bacterial counts were performed by plat-
ing serial 10-fold dilutions of this suspension on MHA
plates. Control biofilm samples were not exposed to an-
tibiotics. Minimum Biofilm Eradication Concentration
(MBEC) was calculated as the minimum concentration
of tested antibiotic able to eradicate preformed biofilm.
Microscopic analyses
Kinetics of biofilm formation by S. pseudintermedius
strain DSM 25713 and its architecture were assessed by
scanning electron microscopy (SEM) and environmental-
SEM (ESEM), respectively. The effects of exposure to
several gentamicin concentrations as well as the ultra-
structure of biofilm formed under dynamic incubation
were evaluated by confocal laser scanning microscopy
(CLSM). i) SEM and ESEM assays. Biofilm formation kin-
etics in TSB was monitored - under static conditions,
without serum, at 37 °C, and at pH 7.1 - in 35 mm-tissue
culture polystyrene dish (Becton, Dickinson and Com-
pany) at different time periods (30 min, 1, 2, 4, 8, 24, 48,
and 72 h). Samples were then fixed in a mixture of 2 %
paraformaldehyde (Electron Microscopy Sciences, Hat-
field, PA, USA) + 2 % glutaraldehyde (Sigma-Aldrich) [vol/
vol] in 0.15 M sodium cacodylate buffer (pH 7.4; Fluka),
with 0.1 % alcian blue (Sigma-Aldrich). Samples were
post-fixed for 90 min at room temperature in 1 % OsO4
[vol/vol] (Electron Microscopy Sciences) in 0.15 M caco-
dylate buffer, then dehydrated in an ascending ethanol
series (50, 70, 80, 95, and twice 100 %; 10 min/each), dried
for 30 min with hexamethyldisilazane (Polysciences Inc.,
Warrington, PA, USA), and finally air-dried. Specimens
were coated with gold-palladium by Polaron E5100 II
(Polaron Instruments Inc.), and then observed with a
Philips XL30CP scanning electron microscope in the
high-vacuum mode at 15 kV. In a parallel experiment, a
72 h-old biofilm sample was fixed and post-fixed as de-
scribed above, and directly observed using a Zeiss EVO
(Carl Zeiss SpA, Arese, Milan, Italy). ii) CLSM assay.
Briefly, 48 h-biofilms were allowed to grow on polystyrene
as described for SEM analysis, then exposed to gentamicin
at different concentrations (from 1x to 128xMIC) for afurther 24 h. Untreated biofilms were used as controls.
In a parallel series of experiments, biofilm was allowed
to grow under dynamic conditions in a flow cell system
in the absence of antibiotics, as described above. Both
static and flow cell biofilms were stained with Live/Dead
BacLight kit (Molecular Probes Inc., Eugene, USA) and
Concanavalin A (Alexa Fluor 647 coniugate; Molecular
Probes Inc.). Static biofilm samples formed on polystyr-
ene were placed in an Attofluor cell-chamber (Molecu-
lar Probes Inc.) before observation. CLSM analysis was
performed with an LSM 510 META laser scanning
microscope attached to an Axioplan II microscope (Zeiss
Italia, Arese, Milan, Italy). Depth measurements were
taken at regular intervals across the width of the de-
vice. To determine biofilm structure, a Z-series of 25
optical planes at xy resolution of 512×512 pixel (68.4 ×
68.4 μm) with a thickness of 1.00 μm was taken
throughout the biofilm. Both SEM and CLSM repre-
sentative images were captured and processed for dis-
play using Photoshop (Adobe Systems Inc., San Jose,
California) software.
Statistical analysis and biofilm interpretative criteria
All experiments were carried out at least in triplicate and
repeated at least on two different occasions. Differences
were assessed by unpaired-t test (standardization of in vitro
model of biofilm formation), ANOVA+Newman-Keuls
multiple comparison post-test (effect of serum and pH both
on biofilm formation and bacterial growth), chi-square test
(percentage of reduction of both biofilm biomass formation
and biofilm viability), or Kruskall-Wallis + Dunn’s multiple
comparison post-test (kinetic of biofilm formation). Statis-
tical analysis of results was conducted with GraphPad
Prism version 6.00 (GraphPad software Inc.; San Diego,
CA, USA), considering as statistically significant a p value
of < 0.05.
The low cut-off value for biofilm formation was repre-
sented by 3 SDs above the mean OD492 of control wells
(containing bacteria-free medium) [20].
To evaluate the effect of serum and pH on biofilm for-
mation, biofilm levels were normalized for bacterial growth
by calculating the specific biofilm formation (SBF) index:
SBF = (ODbiofilm - ODNC)/ODgrowth in which ODbiofilm is
the OD492 of the stained biofilm, ODNC is the OD492 of
the stained negative control wells (to eliminate unspecific
or abiotic OD values), and ODgrowth is the OD600 of cells
grown in broth.
The percentage of inhibition of biofilm formation by
antibiotics tested at sub-inhibitory concentrations was
calculated as follows: (1 - ODexp/ODUC) × 100 in which
ODexp is the OD492 of the stained antibiotic-exposed



















































































Fig. 1 Standardization of experimental conditions for biofilm formation
by S. pseudintermedius strain DSM 25713 on polystyrene surface. Effect
of dynamic (filled squares) or static (filled triangles) incubation,
incubation time (24, 48, and 72 h), and inoculum concentration
(105, 106, and 107 CFU/mL) on biofilm biomass formation, as assessed
by spectrophotometric assay. Values are means ± SDs (n = 6).
***p < 0.001, dynamic vs static, unpaired-t test
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Standardization and optimization of biofilm growth
S. pseudintermedius strain DSM 25713 biofilm growth
on polystyrene, as assessed by crystal violet assay, under
different experimental conditions is summarized in Fig. 1.
A similar trend was observed, regardless of the inoculum
size considered (105, 106 or 107 CFU/ml). Specifically, al-
though significantly higher (p < 0.001) biofilm formation
occurred following 24 h-incubation under dynamic condi-
tions compared to static ones, we observed an opposing
trend at 48 and 72 h-incubation (p < 0.001). Maximum
biofilm amount was produced at 107 CFU/ml after 72 h
of incubation, while no statistically significant differ-
ences were found among the tested inoculum sizes
(OD492: 2.698, 2.423, and 2.491, at 10
7, 106, and 105 CFU/
ml, respectively; p > 0.05). Therefore, an inoculum size
of 107 CFU/ml, and static incubation were used for op-
timal biofilm formation by S. pseudintermedius on a poly-
styrene surface. Since no statistically significant differences
in biofilm biomass formation were observed between 48
and 72 h of incubation, we choose to allow the biofilm to
grow for 48 h and then expose it to antibiotics for another
24 h in the evaluation of antibiotic activity against pre-
formed biofilm.
Effects of serum and pH on biofilm formation
The combined effects of different serum concentra-
tions and pH values on biofilm formation by S. pseu-
dintermedius strain DSM 25713 are summarized in
Fig. 2.
In the absence of serum, biofilm formation at pH 7.1
was significantly higher than that obtained at pH 5.5 or
8.7 (SBF: 5.33 ± 1.06 vs 2.82 ± 1.25 and 3.10 ± 1.05, re-
spectively; p < 0.05) (Fig. 2a). Furthermore, considering the
criteria proposed by Stepanovic et al. [20] S. pseudinter-
medius strain DSM 25713 continuously demonstrated a
strong capacity to produce biofilm (mean OD492 > 0.280),
regardless of the pH value considered.
In the presence of serum the ability to form biofilm was
significantly affected, regardless of the pH value tested.
Specifically, the amount of biofilm was reduced compared
to the control, with ranges of 45.3-87.5 %, 74.3-95.5 %,
and 21.9-96.5 % at pH values of 5.5, 7.1, and 8.7, respect-
ively (Fig. 2a).
Polystyrene pre-treatment with serum significantly re-
duced biofilm formation under acidic conditions, but
only in the presence of 1:2 and 1:10 serum (reduction vs
control: 59.4 and 78.5 %, respectively), and neutral pH
(82.7-88.3 %). At pH 8.7, coating with serum did not sig-
nificantly reduce biofilm formation (Fig. 2a). The anti-
biofilm effect was shown to be dependent only upon
concentration levels in the case of free serum, regardless































































































































































Fig. 2 Effect of serum and pH on biofilm formation and growth by S. pseudintermedius strain DSM 25713. (a) Serum was tested against biofilm
formation at various dilutions (1:2, 1:10, and 1:100), as free or adsorbed to polystyrene, under different pH (5.5, 7.1, and 8.7). Control wells contained
bacteria but not serum. Biofilm biomass amount was measured by crystal violet assay, then normalized on bacterial growth by calculating the specific
biofilm formation (SBF) index (see Materials and Methods). (b) The effect of free serum against bacterial growth was assessed by measuring OD600 of
cell grown in broth following 24 h-incubation. Results are means + SDs (n = 9). *p < 0.05, **p < 0.01, and ***p < 0.001, ANOVA+ Newman-Keuls multiple
comparison post-test
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values of supernatant culture that were measured
following 24 h-incubation, planktonic growth of S.
pseudintermedius strain DSM 25713 was significantly
enhanced in the presence of serum. This effect was
more relevant at pH 7.1 and 8.7, when serum was ef-
fective at both 1:2 and 1:10 (Fig. 2b). In the absence of
serum, S. pseudintermedius strain DSM 25713 growth
was pH-dependent, with maximum result at pH 8.7
(OD600, mean ± SD: 0.583 ± 0.370 vs 0.337 ± 0.071 and
0.107 ± 0.067 at pH 8.7, 7.1 and 5.5, respectively; p <
0.001).Susceptibility of planktonic cells to antibiotics
In vitro susceptibility of S. pseudintermedius strain DSM
25713 planktonic cells to chloramphenicol, gentamicin,
cefoxitin, linezolid, rifampicin, tigecycline, tetracycline,
and vancomycin is summarized in Table 1.
MIC values showed that rifampicin is the most active
antibiotic among those tested (MIC: 0.03 μg/ml). On the
contrary, cefoxitin and chloramphenicol were the least
active drugs (MIC: 16 and 32 μg/ml, respectively). The
comparative evaluation of MIC and MBC values showed
bactericidal activity only for cefoxitin, gentamicin, and
vancomycin (MBC/MIC < 4).
Table 1 In vitro antibiotic susceptibility of planktonic and biofilm
S. pseudintermedius strain DSM 25713 cells. MIC, Minimum
Inhibitory Concentration; MBC, Minimum Bactericidal
Concentration; MBEC50 and MBEC90, Minimum Concentrations
Eradicating respectively 50 % and 90 % of Biofilm viability,
compared to untreated controls (100 % viability). Assays were
performed in triplicate and repeated on two different occasions
(n = 6). Values are mg/L
Antibiotics Planktonic cells Biofilm cells Cmax
a
MIC MBC MBEC50 MBEC90
Chloramphenicol 32 256 128 4,096 16.9 [49]
Gentamicin 0.5 0.5 32 32 5-12 [50]
Cefoxitin 16 32 16 1,024 20 [51]
Linezolid 4 32 4 1,024 21.2 [52]
Rifampicin 0.03 0.5 0.03 0.06 10 [53]
Tigecycline 0.5 8 0.5 64 0.25-2.8 [54]
Tetracycline 0.5 8 0.5 64 2 [55]
Vancomycin 2 2 16 32 25 [56]
aMaximum concentration of drug in serum; references are shown in parentheses
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formation
The effects of antibiotics tested at sub-inhibitory con-
centrations (1/2x, 1/4x, and 1/8xMIC) against biofilm
formation are shown in Fig. 3.
Generally, sub-inhibitory concentrations caused a sig-
nificant reduction in the formation of biofilm in a dose-
dependent manner, although striking differences were
observed among the antibiotics tested.
Cefoxitin proved to be the most active antibiotic since
at 1/8xMIC it provoked a reduction in biofilm forma-
tion of S. pseudintermedius strain DSM 25713 that wasFig. 3 In vitro activity of antibiotics at sub-inhibitory concentrations against
biomass formed during 24 h-incubation was measured, using the crystal viole
1/4x, and 1/8xMIC. Results were plotted as percentage of biofilm biomass form
100 % biofilm biomass) (n = 6). The dotted line indicates a reduction in biofilmsignificantly higher than other antibiotics (% biofilm bio-
mass vs control, 13.5 ± 4.9). Chloramphenicol, gentamicin,
linezolid, rifampicin and tigecycline also caused a signifi-
cant reduction in biomass regardless of the concentrations
tested. On the contrary, tetracycline and vancomycin were
the least active against antibiotics, showing an inability to
affect biofilm formation at concentrations equal to 1/
8xMIC or both at 1/4x and 1/8xMIC, respectively.
Effects of antibiotics on preformed biofilms
The activity of antibiotics, tested at concentrations equal
to or a multiple of MIC, on mature biofilms is summa-
rized in Table 1 and Fig. 4.
The comparative evaluation between MIC and MBEC
values indicated that rifampicin is the most active anti-
biotic against preformed biofilms (MBEC50 and MBEC90:
1x and 2xMIC, respectively) (Table 1). Other antibiotics
showed a reduced activity, although at different extents.
In particular, vancomycin showed MBEC50 and MBEC90
of 8x and 16xMIC, respectively, followed by cefoxitin
(MBEC50 and MBEC90: 1x and 64xMIC, respectively).
Chloramphenicol (MBEC50 and MBEC90: 4x and 128x
MIC, respectively), linezolid, tetracycline and tigecyc-
line (MBEC50 and MBEC90: 1x and >128xMIC, respect-
ively) showed comparable activity. Gentamicin was the
least active among the antibiotics tested (MBEC50 and
MBEC90: 64xMIC), even stimulating the production of
significantly higher biofilm amounts at 1x and 2xMIC,
compared to controls (Fig. 4). All antibiotics exhibited
a dose-dependent effect, except for linezolid, rifampi-
cin, and tigecycline. Importantly, none of the antibi-
otics studied were able to eradicate mature biofilms at
the concentrations tested (Fig. 4).biofilm formation by S. pseudintermedius strain DSM 25713. Biofilm
t assay, in the presence of antibiotics at concentrations equal to 1/2x,
ed in the presence of antibiotic, compared to controls (not exposed,
biomass of at least 20 % vs control (p < 0.001, chi-square test)
Fig. 4 In vitro effect of antibiotics against preformed biofilm by S. pseudintermedius strain DSM 25713. Biofilms allowed to form following 48 h-incubation
were exposed for further 24 h to each antibiotic at concentrations equal or multiple of MIC. Results are expressed as percentage of biofilm’s viability – as
assessed by viable colony count - compared to control (unexposed, 100 % viability) (n = 6). The dotted line indicates a reduction in biofilm viability of at
least 20 % vs control (p < 0.001, chi-square test)
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MBEC90 values, rifampicin was confirmed to be the most
active antibiotic (MBEC90: 0.06 μg/ml), followed by vanco-
mycin and gentamicin (MBEC90: 32 μg/ml), while chlor-
amphenicol was the least effective (MBEC90: 4,096 μg/ml)
(Table 1).
Microscopic analysis of biofilms formed under static and
dynamic conditions
Representative CLSM images of biofilm formed by S.
pseudintermedius strain DSM 25713 are shown in Fig. 5.
Under static incubation, S. pseudintermedius is able to
form a dense biofilm with “mushroom-like” architecture
consisting of aggregates and microcolonies that almost
completely cover the polystyrene surface. The biofilm
formed in flow cell chamber, under dynamic conditions,
was shown to be significantly more complex, in terms of
thickness and cellularity, compared to the biofilm formed
under static incubation (mean thickness, 25.4 vs 14.2 μm,
respectively; p < 0.05) (Figs. 5a-b).
Corresponding to the results obtained with the viable
cell count testing, there were variations in biofilm amount
and morphology observed in a dose dependent response
to gentamycin. At 1xMIC, biofilm amount was increased,
while at 8xMIC and above, there were alterations in the
three-dimensional structure of the biofilms seen, and
some disruption of established biofilms.
SEM analysis was performed to monitor the biofilm
formation kinetics throughout 72 h of incubation, and to
analyze the morphological characteristics of biofilm
(Fig. 6). After only 30 min, single cocci randomly adhered
to polystyrene (adhesion phase). After 4 h, early biofilm
appeared as small microcolonies, consisting mainly ofclustered cells without any evidence of EPS (Fig. 6b). Dur-
ing the maturation phase (8 to 72 h), microcolonies di-
mensionally increased, covering most of the surface
(Figs. 6c-f). In particular, the addition of alcian blue to the
fixative solution revealed a significant production of EPS
after 48 h, appearing as an extensive network of filaments.
EPS covered most of the surface, surrounded biofilm cells
and bridged these to the substratum (Figs. 6 g-h).
The kinetics of biofilm formation by S. pseudinterme-
dius strain DSM 25713 on the surface of polystyrene
wells over 72 h is shown in Fig. 6i. Viable counts con-
firmed the findings obtained during SEM analysis. In
particular, bacteria were shown to attach rapidly, within
1 h of incubation (median: 1.5 x 105 CFU/well), then the
biofilm formation increased over time up to 48 h (me-
dian: 1.6 x 108 CFU/well).
We also performed ESEM to obtain a deeper and more
realistic view of the 3D biofilm structure, cell arrangement
and matrix shape. ESEM analysis confirmed the heteroge-
neous architecture of biofilm formed by S. pseudinterme-
diusDSM 25713, and disclosed the presence of a highly
hydrated extracellular matrix within the surrounding cells
(Fig. 7).
Discussion
Our results demonstrate, for the first time, that human
S. pseudintermedius has the potential to grow as an
antibiotic-resistant biofilm. In fact, confocal and electron
microscopy revealed that under static conditions, simi-
larly to wound infections, S. pseudintermedius strain
DSM 25713 is able to form a well-structured biofilm,
consisting of multilayered, mushroom-shaped microco-
lonies embedded in an abundant amount of EPS matrix,
Fig. 5 Confocal Laser Scanning Microscopy of biofilm formed by S. pseudintermedius strain DSM 25713. Biofilm was allowed to form for 48 h at
37 °C, in absence of serum, under both (a) static, and (b) dynamic (flow cell chamber) conditions. Static biofilms were further treated for 24 h
with increasing gentamicin concentrations (1x-128xMIC). Representative images of biofilm exposed at (c) 1x and (d) 128xMIC gentamicin are
shown. Orthogonal images z are projections of x and y planes, collected within the biofilm as indicated by the green and red lines in the top
view. Image capture was set for simultaneous visualization of red (Propidium iodide-stained dead cells), green (Syto-9-stained viable cells), and
blue (Concanavalin A-stained EPS) fluorescence. Magnification, x100
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SEM observation revealed that EPS, critical for at-
tachment and structural development of mature bio-
film [21], forms an extensive network of filaments
stretching among cells as well as between cells and the
polystyrene surface.
Furthermore, CLSM analysis of S. pseudintermedius
biofilm formed under dynamic conditions, such as those
observed inside a venous or urinary catheter, revealed a
more complex ultrastructure compared with that ob-
served under static conditions, with significant increases
in both cellularity and thickness. These findings show the
potential for S. pseudintermedius to cause an implant-
associated infection, which is consistent with previous
reports of S. pseudintermedius causing infections asso-
ciated with intravascular devices (cardiac devices, cath-
eters) [3–5].
The ability of bacteria to form biofilms has recently
been demonstrated as a cause for the chronicization of
wound infections [22–25]. Various factors may modulate
in vivo biofilm development at a wound infection site[26–29]. For example, serum proteins (i.e. fibrinogen
and albumin) deposited onto host tissues provide receptor
binding sites for bacterial adhesion and biofilm formation
[26–28]. In addiction, wound exudate pH, modulated dur-
ing infection and healing processes, affects bacterial
growth and density in biofilm populations [29]. Therefore,
the present study examined the ability of the S. pseudinter-
medius strain DSM 25713 to form biofilms in the presence
of serum and at different pH values, conditions relevant to
the wound environment.
Our results show that the presence of human serum
negatively affects S. pseudintermedius biofilm formation,
although it is worthy to note that the ability to form
biofilm was retained even in the presence of serum
concentrations well above those observed at the site of
infection. Our findings are in agreement with those
found for S. aureus and P. aeruginosa [30, 31], but dis-
cordant with studies focused on other Gram-positive
bacteria - including Streptococcus mitis, S. aureus, and
coagulase-negative staphylococci – whose adherence
was not significantly inhibited by serum [32–34].
Fig. 6 Kinetic of biofilm formation, through 72 h-incubation, by S. pseudintermedius strain DSM 25713 onto polystyrene. (a-f) Representative SEM
images of biofilm formation after 1, 4, 8, 24, 48, and 72 h of incubation, respectively. Magnification (x1.000). (g, h) Magnification (x20.000) of (e) and (f),
respectively. Cocci are surrounded by EPS appearing as an extensive network of filaments stretched among cells and between these and the substratum.
(i) Kinetic of biofilm formation as assessed by viable count. Maximum, median, and minimum values are shown in each box (n = 6)
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terial effect since, according to previous findings obtained
for P. aeruginosa [30], serum significantly promoted the
growth of S. pseudintermedius, regardless of the pH levels
tested.
Precoating polystyrene resulted in a significant decrease
in biofilm formation, when compared to the uncoated
controls, even in the presence of 1 % serum, thus suggest-
ing that serum components, such as albumin, adsorbed on
the substratum surface prevent bacterial attachment by
acting as a physical barrier between bacteria and the sub-
stratum, or by making the surface less hydrophobic. In
particular, the anti-adhesive effect of human serum albu-
min seems related to the competitive binding of this pro-
tein to an accretion surface or bacterial cells [35]. Further
studies are warranted in this regard.
The reduction of S. pseudintermedius attachment and
biofilm formation that we observed in the presence of
free serum also suggests that serum might inhibit biofilmformation by additional mechanisms other than coating
the surface. As previously observed for P. aeruginosa [30],
particular components of serum could directly interact
with S. pseudintermedius thus inhibiting biofilm formation.
Knowledge of the anti-biofilm activity of antibiotics is
critical for the management of biofilm-related infections,
such as chronic wounds. In the present work, we selected
gentamicin, cefoxitin, linezolid, rifampicin, tigecycline and
vancomycin because of their relevance in the prevention
and treatment of staphylococcal infections, particularly
those caused by methicillin-resistant S. aureus (MRSA).
The older drugs chloramphenicol and tetracycline were
also considered, since older antibiotics are frequently be-
ing re-evaluated for treatment of multi-drug resistant and
biofilm-based infections, due to the decrease in develop-
ment of novel antimicrobials [36].
Since the bacterial adhesion to a surface is a critical
prerequisite for biofilm formation, we first investigated
the prophylactic potential of the selected antibiotics by
Fig. 7 ESEM images of biofilm formed by S. pseudintermedius strain
DSM 25713 onto polystyrene following 72 h-incubation. (a) Biofilm
exhibited spatially heterogeneous organization, as suggested by
the presence of “mushroom-like” structures (as indicated by arrows).
Magnification: x3.000. (b, c) Multilayered organization with the
presence of bacteria under EPS matrix (as indicated by arrows).
Magnification: x12.500 and x20.000, respectively
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both adhesion and biofilm biomass formation. All antibi-
otics showed both anti-adhesive and anti-biofilm effect,although to different extents. Particularly, cefoxitin exhib-
ited the strongest activity, demonstrating the ability to re-
duce biofilm biomass formation more than 90 % regardless
of the tested concentration. On the contrary, the smallest
effect was observed for vancomycin, since it was ineffective
against biofilm formation even at 1/8x and 1/4xMIC. Anti-
biotic concentrations effective against biofilm formation
were not active against planktonic growth, and no correl-
ation was found between the ability to kill planktonic cells
and the activity on biofilm formation. Together, these find-
ings suggest that the tested antibiotics interfere with S.
pseudintermedius biofilm formation by mechanisms other
than direct antimicrobial activity.
Chronic infections, including wounds and implant-
associated infections, often persist despite antibiotic
therapy and the innate and adaptive immune and in-
flammatory responses of the host because due to the
presence of biofilm-growing bacteria [37]. Clinically
used antibiotics and their dose regimens were in fact
classically developed to treat infections due to the pres-
ence of planktonic bacteria, therefore they are ineffect-
ive in the eradication of biofilm-based infections at the
same doses. To evaluate the antibiotic activity against
preformed biofilm by S. pseudintermedius strain DSM
25713, MBEC of each antibiotic was measured follow-
ing 24 h-exposure of 48 h-old biofilms to bactericidal con-
centrations. Overall, MBEC values were greater than
CLSI-suggested planktonic MIC breakpoint for resistance.
Comparative evaluation of MBEC90/MIC ratio - an im-
portant parameter for choosing the antibiotic in the
treatment of biofilm-associated infections - indicated
rifampicin as the most active antibiotic (MBEC90/MIC:
2), in agreement with previous in vitro and in vivo
studies focused on S. aureus biofilm [38, 39]. Other an-
tibiotics tested showed a significantly reduced activity
against preformed S. pseudintermedius biofilm as sug-
gested by MBEC90 values ranging from 16xMIC (vanco-
mycin) to at least 128xMIC (linezolid, tigecycline,
chloramphenicol, and tetracycline). In agreement with
our findings, Leite et al. [40] found that rifampicin was
more active than linezolid against S. epidermidis bio-
films, while Parra-Ruiz et al. [41] observed that linezo-
lid was not bactericidal against mature biofilms formed
by S. aureus. Our results with S. pseudintermedius bio-
films are consistent with the findings of vancomycin
antibiotic-lock resistant catheter-associated S. pseudin-
termedius bacteremia described by Chuang et al. [4],
being due to the presence of resistant biofilms.
The clinical relevance of our results is even more evident
if peak serum antibiotic concentrations are considered.
With the exception of rifampicin, none of the tested antibi-
otics would have been able to eradicate biofilm even when
used at multiples of achievable serum levels from currently
recommended dosages. In particular, chloramphenicol,
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256 times the maximum attainable concentration in
serum to achieve 90 %-inhibition of biofilm viability.
The relative lack of efficacy of linezolid and tigecycline
in eradicating S. pseudintermedius cells embedded in
biofilm is consistent with prior in vitro studies con-
cerning staphylococcal biofilms [42, 43], raising a spe-
cial clinical concern since these antibiotics are used as
the "treatment of last resort" against potentially life-
threatening MRSA infections that are sometimes not
treatable with any other antibiotics.
The mechanisms of biofilm resistance are likely multi-
factorial and vary according to the considered specie,
and remain still unclear [44]. Although the present work
was not focused on mechanisms underlying the inherent
antibiotic-resistance of S. pseudintermedius biofilm, the
complex biofilm structure, as revealed by microscopic
analysis, might play a role in this regard by physically/
chemically sequestering the antibiotic, thus delaying its
penetration through the biofilm.
Gentamycin, whose MBEC90 is 2.6 to 6.4 times higher
than peak serum, may be an example of this, where inter-
actions between the positively charged antibiotic and the
negatively charged components of EPS likely are respon-
sible for preventing ready diffusion of the antimicrobials
through the biofilm matrix to the bacteria [44]. Despite
the potential inherent resistance of biofilms to aminogly-
cosides, the increased concentrations afforded by topical
therapy [7, 45], or treatment of wounds where aminogly-
cosides are relatively concentrated [46], may still allow for
the successful eradication of biofilm infections.
Conclusions
Some clinical implications can be drawn on the basis of
our results. First, while S. pseudintermedius is a com-
mensal in dogs, our results show significant concern for
the organism as a pathogen in people, especially when as-
sociated with temporary or permanent implants [3–5].
Second, serum reduces, but does not prevent, S. pseudin-
termedius biofilm formation at concentrations measured
in infected wound exudate. Third, S. pseudintermedius is
able to form mature biofilm inherently resistant to antibi-
otics at concentrations well above those observed in
serum, including linezolid, tigecycline, and vancomycin
which are commonly considered as “last resort antibiotics”
against methicillin-resistant staphylococci. This is particu-
larly relevant in chronic GvHD patients where skin wound
infections account for the majority of deaths [47]. Fourth,
in vitro models relevant to the in vivo situation are needed
for adequately assessing antibiotic activity in the case of
biofilm-related infections, such as for wounds. Using our
model, rifampicin was measured to be the most effective
antibiotic against S. pseudintermedius strain DSM 25713
biofilms, however clinical use of rifampicin as a sole agentshould be appreciated cautiously due to the rapid selection
of rifampicin-resistant mutants [48].
The data presented here are in vitro results and, there-
fore, cannot completely explain or represent S. pseudin-
termedius biofilm-related infections. Both in vitro and
in vivo models representative of the wound environment
are required to gain new insights into the mechanisms
underlying bacterial adhesion and biofilm formation
aimed at designing new therapeutic strategies.
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